HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST PREVENTS ADRENOCORTICOTROPIN, BUT NOT INTERLEUKIN-6 RESPONSES TO BACTERIAL-ENDOTOXIN IN RATS

被引:47
|
作者
SCHOTANUS, K [1 ]
TILDERS, FJH [1 ]
BERKENBOSCH, F [1 ]
机构
[1] FREE UNIV AMSTERDAM,FAC MED,NEUROSCI RES INST,DEPT PHARMACOL,VAN DER BOECHORSTR 7,1081 BT AMSTERDAM,NETHERLANDS
关键词
D O I
10.1210/en.133.6.2461
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present study was designed to analyze the role of endogenous interleukin-1 (IL-1) in the ACTH, corticosterone (CORT), and IL-6 responses of rats to bacterial endotoxin. Recombinant rat IL-1beta (rIL-1beta) when given ip resulted in dose-dependent increases in plasma ACTH, CORT, and IL-6 concentrations. Plasma ACTH and CORT responses could be induced by low rIL-1beta doses that did not elevate plasma IL-6 levels. The half-maximally effective dose of rIL-1beta was less than 0.6 mug/kg for the ACTH and CORT responses and higher than 2.5 mug/kg for the IL-6 response. Time-course studies indicated that plasma ACTH and CORT concentrations were already elevated 30 min after the injection of rIL-1beta (2.5 mug/kg, ip), with peak values after 1-2 h, followed by a subsequent decline. In contrast, plasma IL-6 concentrations became elevated 2 h after the injection of rIL-10. In another set of experiments, the administration of endotoxin resulted in a dose-dependent elevation of the plasma ACTH, CORT, and IL-6 concentrations. The dose-response characteristics for ACTH, CORT, and IL-6 were different. The half-maximally effective dose for the ACTH and CORT, and IL-6 responses were approximately 2.5 mug/kg and more than 10 mug/kg, respectively. Time courses of plasma ACTH, CORT, and IL-6 responses to endotoxin (2.5 mug/kg, ip) were similar, with peak values measured after 2 h. When given alone, the human IL-1 receptor antagonist (IL-1RA; 1 or 2.5 mg/kg, ip) did not affect resting plasma ACTH and CORT concentrations and reduced plasma IL-6 concentrations in one experiment. At a dose of 1 mg/kg, IL-1RA inhibited ACTH and IL-6 responses to rIL-1beta (2.5 mug/kg, ip) by 75% and 90%, respectively. Administration of IL-1RA (2.5 mg/kg, ip) 30 min after endotoxin (2.5 ug/kg, ip) completely prevented the ACTH response and partially inhibited the CORT response, but did not affect the IL-6 response measured 2.5 h after endotoxin administration. We conclude that 1) IL-1 receptors are involved in the ACTH and IL-6 responses to rat IL-1beta; 2) the ACTH response, but not the IL-6 response, to a low dose dose of endotoxin in rats requires IL-1 receptor activation by endogenous produced IL-1; and 3) circulating IL-6 is not a prime mediator involved in ACTH and CORT responses to low doses of rIL-1beta and endotoxin.
引用
收藏
页码:2461 / 2468
页数:8
相关论文
共 50 条
  • [31] Balance of interleukin-1β and interleukin-1 receptor antagonist in human periapical lesions
    Shimauchi, H
    Takayama, S
    Imai-Tanaka, T
    Okada, H
    JOURNAL OF ENDODONTICS, 1998, 24 (02) : 116 - 119
  • [32] INTERLEUKIN-1 AND INTERLEUKIN-6 IN PSORIASIS
    PRENS, EP
    BENNE, K
    VANDAMME, J
    BAKKUS, M
    BRAKEL, K
    BENNER, R
    VANJOOST, T
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (06) : S121 - S124
  • [33] INTERLEUKIN-1 RECEPTOR ANTAGONIST BLOCKS SOMNOGENIC AND PYROGENIC RESPONSES TO AN INTERLEUKIN-1 FRAGMENT
    OPP, MR
    POSTLETHWAITE, AE
    SEYER, JM
    KRUEGER, JM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (09) : 3726 - 3730
  • [34] SYNERGISTIC ROLES OF INTERLEUKIN-6, INTERLEUKIN-1, AND TUMOR-NECROSIS-FACTOR IN THE ADRENOCORTICOTROPIN RESPONSE TO BACTERIAL LIPOPOLYSACCHARIDE INVIVO
    PERLSTEIN, RS
    WHITNALL, MH
    ABRAMS, JS
    MOUGEY, EH
    NETA, R
    ENDOCRINOLOGY, 1993, 132 (03) : 946 - 952
  • [35] COMPARISON OF THE EFFECTS OF RECOMBINANT INTERLEUKIN-6 AND RECOMBINANT INTERLEUKIN-1 ON NONSPECIFIC RESISTANCE TO INFECTION
    VANDERMEER, JWM
    HELLE, M
    AARDEN, L
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (02) : 413 - 416
  • [36] Graves' ophthalmopathy and gene polymorphisms in interleukin-1α, interleukin-1β, interleukin-1 receptor and interleukin-1 receptor antagonist
    Khalilzadeh, Omid
    Anvari, Mehdi
    Esteghamati, Alireza
    Mahmoudi, Mahdi
    Tahvildari, Maryam
    Rashidi, Armin
    Khosravi, Farideh
    Amirzargar, Aliakbar
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 37 (06): : 614 - 619
  • [37] Effect of recombinant human erythropoietin on interleukin-1 beta and interleukin-6 in patients on maintenance hemodialysis
    Sayinalp, N
    Erdem, Y
    Haznedaroglu, IC
    Dundar, S
    Caglar, S
    Kirazli, S
    CLINICAL NEPHROLOGY, 1995, 44 (06) : 404 - 404
  • [38] Balance Between Interleukin-1β and Interleukin-1 Receptor Antagonist in the Development of Atherosclerosis - A Polymorphism in the Interleukin-1 Receptor Antagonist -
    Iida, Shinichiro
    Komiyama, Nobuyuki
    CIRCULATION JOURNAL, 2009, 73 (08) : 1401 - 1402
  • [39] EFFECT OF BACTERIAL-ENDOTOXIN AND INTERLEUKIN-1 ON PROSTAGLANDIN BIOSYNTHESIS BY THE HIPPOCAMPUS OF MOUSE-BRAIN - ROLE OF INTERLEUKIN-1 RECEPTORS AND GLUCOCORTICOIDS
    WEIDENFELD, J
    CRUMEYROLLEARIAS, M
    HAOUR, F
    NEUROENDOCRINOLOGY, 1995, 62 (01) : 39 - 46
  • [40] Lipopolysaccharide from Actinobacillus actinomycetemcomitans stimulates production of interleukin-1β, tumor necrosis factor-α, interleukin-6 and interleukin-1 receptor antagonist in human whole blood
    Blix, IJS
    Helgeland, K
    Hvattum, E
    Lyberg, T
    JOURNAL OF PERIODONTAL RESEARCH, 1999, 34 (01) : 34 - 40